CLINICAL STUDY ABSTRACTS
Journal of Dermatology October, 1994, volume 21, issue 10, pp. 729-31
NODULOCYSTIC ACNE: ORAL GUGGULIPID VERSUS TETRACYCLINE
Dr. Devinder M. Thappa, Dr. Jaideep Dogra
Department of Dermatology, C.G.H.S., Bajaj Nagar, Jaipur, India
Twenty patients with nodulocystic acne were randomly allocated to one of two treatment schedules: 1) Tetracycline 500 mg or 2) Tablets of Gugulipid (equivalent to 25 mg guggulsterone). Both were taken twice daily for 3 months, and both produced a progressive reduction in the lesions in the majority of patients. With tetracycline, the percentage reduction in the inflammatory lesions was 65.2% as compared to 68% with gugulipid; on comparison, this difference was statistically insignificant (P > 0.05). Follow-up at 3 months showed a relapse in 4 cases on tetracyline and 2 cases on gugulipid. An interesting observation was that the patients with oily faces responded remarkably better to gugulipid.
Read this abstract on the PubMed website
Indian Journal of Dermatology, Venereology and Leprology, 1990 Issue 56, pp. 381-383
ORAL GUGGULIPID IN ACNE VULGARIS MANAGEMENT
Dr. Jaideep Dogra, Dr. Neelam Aneja, Dr. V. N. Saxena
Gugulipid is the standardized extract of the oleo-resin of Commiphora mukul, an Inidian medicinal plant. The active ingredients are two Z and E gugglesterones. Gugulipid is an effective hypolipidemic agent that has a marked antilipolytic activity in rats. Considering the pathogenesis of acne vulgaris and the pharmacological properties of gugulipid, this trial was initiated. Thirty patients with moderate to severe acne (greater or equal to Grade 4) were included in this study. Tablets of gugulipid were prescribed in three times per day dosage for six weeks. Responses were excellent in nine patients (30%), good in fourteen patients (47%) and moderate in seven patients (23%). No topical treatment was recommended except for local skin hygiene. The drug showed excellent tolerance. Only three patients reported relapse when examined at three months followup.
Home | Frequently Asked Questions | Biocentrics - The Company | Clinical Trial Details | Contact Us